Transition Bio
Biotechnology
$58.4Mraised in 3 rounds
50+people
2020founded
13stories in the press
Overview
Solving the Unsolvable Redefining drug discovery at the molecular level By combining the technology and data engine of Harvard’s Weitz Lab and the University of Cambridge’s Knowles Lab, we created the only end-to-end condensate drug discovery platform built on molecular insights.More About Us ⟶.
Key facts
These are the key facts about Transition Bio on Alion as of Nov 13, 2026. Transition Bio is headquartered in Cambridge, United States. It was founded in 2020. It has raised $52.4M in 2 funding rounds. The latest round is Venture - Series Unknown of $13.3M, announced in 2024.
- Headquarters
- Cambridge, United StatesAlion company profile, updated Nov 13, 2026
- Founded
- 2020Alion company profile, updated Nov 13, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $52.4MSum of 2 equity rounds Alion knows
- Latest round
- Venture - Series Unknown · $13.3M · Oct 11, 2024SEC Form D filing · sec.gov
Official records
People
George Martin
Executive Officer, Director
Stephanie Torruella
Executive Officer
Tuomas Knowles
Director
Gregory Miller
Executive Officer, Director
Martin Kulander
Executive Officer
Preet Makkar
Executive Officer
Shaan Gandhi
Director
Samuel Cohen
Director
Al Sandrock
Director
Kathy Yi
Director
Connor McDermott
Director
Robert Weeks
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Taiho VenturesVia a fund
Cambridge EnterpriseVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
Transition Bio & Voyager collaborate to advance small molecules targeting TDP-43 in ALS and frontotemporal dementia
Transition Bio & Voyager collaborate to advance small molecules targeting TDP-43 in ALS and frontotemporal dementia
Read more
Report
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally
Read more
Report
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally
Read more
Report
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking...
Read more
Report
Transition Bio Names CEO, CTO, and COO
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
50-200 est. staff
How to cite this page
Alion, "Transition Bio: key facts", as of Nov 13, 2026. https://alion.io/company/transitionbio
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0